ROCKAWAY, NJ, Dec. 15 10, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce store for patients residing in the UK. The site, which can be found at www.gammacore.co.uk, asks patients to complete a health questionnaire in order to purchase a gammaCore Sapphire™ non-invasive vagus nerve stimulation (nVNS) device online. ).
The first product launched on the platform is designed to treat menstrual migraine, supporting the 60% of women who report migraine symptoms associated with their menstrual cycle. This platform will allow patients to have a fully virtual experience by completing a clinical assessment online, having the product delivered to their doorstep and being trained via video calls with a member of the UK customer service team.
“We want to make gammaCore more accessible to patients looking to better manage their primary headaches. With approximately 70% of migraine sufferers being female, the specificity of menstrual migraine is a natural starting point into a new chapter for our business in the online marketplace. We have created a simple assessment process with full clinician supervision providing ongoing customer service as needed,” said Karly Hoggard, Director of Global Business Development at electroCore. “Many women suffering from migraine symptoms each month expect to live with such symptoms, impacting daily life, work, family and social commitments. We are delighted to offer a clinically proven to women looking for solutions to treat their primary headaches, and through this platform we hope to empower people to take ownership of their conditions and regain control.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its noninvasive vagus nerve stimulation therapy platform, initially focused on treating multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraine in adolescent, paroxysmal hemicrania and continuous hemicrania in adults.
For more information, visit www.electrocore.com.
gammaCoreMT (nVNS) is the first non-invasive manual medical therapy applied to the neck as an adjunct therapy to treat migraine and cluster headache through the use of mild electrical stimulation of the vagus nerve that crosses the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed without the potential side effects associated with commonly prescribed medications. When placed on a patient’s neck above the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may result in reduced pain for patients.
gammaCore (nVNS) is cleared by the FDA in the United States for adjunctive use for the preventive treatment of cluster headaches in adult patients, the acute treatment of pain associated with episodic cluster headaches in adult patients, and the acute treatment and preventive of migraine in adolescents (12 years and older) and adult patients. gammaCore is CE marked in the European Union for the acute and/or prophylactic treatment of primary headache (migraine, cluster headache, trigeminal autonomic headache and hemicrania continua) and medication overuse headache in adults.
gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as a pacemaker, hearing aid implant, or other implanted electronic device
- Having a metal device, such as a stent, bone plate, or bone screw, implanted at or near the neck
- Use another device at the same time (eg TENS unit, muscle stimulator) or any portable electronic device (eg cell phone)
The safety and efficacy of gammaCore have not been evaluated in the following patients:
- Adolescent patients with congenital heart problems
- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
- Pediatric patients (under 12 years old)
- Pregnant women
- Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
Please refer to the gammaCore Instructions for Use for all important warnings and precautions before using or prescribing this product.
For more information, please visit www.gammacore.co.uk.
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the activities of electroCore. prospects and plans for clinical and product development; its pipeline or potential markets for its technologies; the timing, results and impact of regulatory, clinical and commercial developments; the Company’s business prospects in the UK (including its e-commerce initiative) and other new markets and other statements which are not historical in nature, in particular those which use terminology such as “anticipates” , “shall”, “expect”, “believe”, “intend”, other words of similar meaning, derivations of these words and use of future dates. Actual results may differ from those projected in the forward-looking statements due to numerous factors, including, but not limited to, the ability to obtain additional funds necessary to pursue ElectroCore’s business and product development plans, the inherent uncertainties associated with the development new products or technologies, the ability to commercialize gammaCore™, the impact and potential effects of COVID-19 on electroCore’s business, results of operations and performance financial statements of electroCore, and any actions electroCore has and may take in response to COVID-19 and any expectations electroCore may have in this regard, competition in the industry in which electroCore operates and general market conditions . All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. , unless required by law. Investors should review all of the information presented here and should also refer to the disclosure of risk factors set forth in reports and other filings by electroCore with the SEC available at www.sec.gov.